Telomir Pharmaceuticals (NASDAQ:TELO) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Telomir Pharmaceuticals (NASDAQ:TELO) issued its earnings results on Thursday. The company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.04, FiscalAI reports.

Telomir Pharmaceuticals Trading Up 3.3%

TELO traded up $0.04 during trading hours on Thursday, hitting $1.27. The company’s stock had a trading volume of 74,851 shares, compared to its average volume of 141,788. Telomir Pharmaceuticals has a fifty-two week low of $1.05 and a fifty-two week high of $3.10. The firm has a market capitalization of $43.66 million, a PE ratio of -3.85 and a beta of -0.21. The company has a 50-day simple moving average of $1.32 and a 200 day simple moving average of $1.33.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Zacks Research upgraded Telomir Pharmaceuticals to a “hold” rating in a research note on Wednesday, March 18th. Wall Street Zen raised Telomir Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, February 21st. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Telomir Pharmaceuticals in a report on Tuesday, April 21st. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Telomir Pharmaceuticals presently has an average rating of “Hold”.

Institutional Trading of Telomir Pharmaceuticals

Several large investors have recently added to or reduced their stakes in TELO. Marshall Wace LLP acquired a new stake in Telomir Pharmaceuticals in the 2nd quarter valued at approximately $95,000. Raymond James Financial Inc. increased its position in shares of Telomir Pharmaceuticals by 4,101.9% during the 3rd quarter. Raymond James Financial Inc. now owns 75,340 shares of the company’s stock valued at $105,000 after purchasing an additional 73,547 shares during the period. Jane Street Group LLC acquired a new position in shares of Telomir Pharmaceuticals during the 2nd quarter valued at $62,000. XTX Topco Ltd acquired a new position in shares of Telomir Pharmaceuticals during the 4th quarter valued at $53,000. Finally, Geode Capital Management LLC increased its position in shares of Telomir Pharmaceuticals by 14.0% during the 4th quarter. Geode Capital Management LLC now owns 223,549 shares of the company’s stock valued at $297,000 after purchasing an additional 27,519 shares during the period.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc (NASDAQ: TELO) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapies for cardiometabolic and fibrotic diseases. Leveraging a proprietary target discovery platform, the company aims to identify and modulate key biological pathways implicated in tissue fibrosis, inflammation and metabolic dysregulation. Its research strategy centers on oral agents intended to address high-unmet-need conditions such as nonalcoholic steatohepatitis (NASH) and systemic fibrotic disorders, where existing treatment options are limited.

The company’s lead development candidate is an oral inhibitor currently in early-phase clinical trials that targets growth factors involved in fibrotic tissue remodeling.